DAMORA THERAPEUTICS, INC. Operating Income
DAMORA THERAPEUTICS, INC. (DMRA) reported Operating Income of -$34.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$34.99M.
- DAMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$30.81M.
- DAMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$201.70M.
- DAMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$3.16M.
- DAMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$210.87M.
- DAMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$22.26M.
- DAMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$39.91M.
- DAMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$61.21M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$34.99M 10-Q · filed 2026-08-10 | -$65.81M 10-Q · filed 2026-08-10 | -$267.50M derived: sum of 3 quarters · filed 2026-08-10 | -$270.66M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | -$30.81M 10-Q · filed 2026-05-12 | -$232.51M derived: sum of 2 quarters · filed 2026-05-12 | -$235.66M derived: sum of 3 quarters · filed 2026-05-12 | -$239.08M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | -$201.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$204.85M derived: sum of 2 quarters · filed 2026-03-19 | -$208.27M derived: sum of 3 quarters · filed 2026-08-10 | -$210.87M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$3.16M 10-Q · filed 2025-11-06 | -$6.58M derived: sum of 2 quarters · filed 2026-08-10 | -$9.18M 10-Q · filed 2025-11-06 | -$16.28M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | -$3.42M 10-Q · filed 2026-08-10 | -$6.02M 10-Q · filed 2026-08-10 | -$13.12M derived: sum of 3 quarters · filed 2026-08-10 | -$16.96M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | -$2.60M 10-Q · filed 2026-05-12 | -$9.70M derived: sum of 2 quarters · filed 2026-05-12 | -$13.54M derived: sum of 3 quarters · filed 2026-05-12 | -$19.12M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | -$7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$10.94M derived: sum of 2 quarters · filed 2026-03-19 | -$16.52M derived: sum of 3 quarters · filed 2026-03-19 | -$22.26M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$3.84M 10-Q · filed 2025-11-06 | -$9.42M derived: sum of 2 quarters · filed 2025-11-06 | -$15.16M 10-Q · filed 2025-11-06 | -$21.83M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$5.58M 10-Q · filed 2025-08-05 | -$11.32M 10-Q · filed 2025-08-05 | -$17.99M derived: sum of 3 quarters · filed 2025-08-05 | -$26.57M derived: sum of 4 quarters · filed 2025-08-05 | |||
| 2024-03-31 | -$5.74M 10-Q · filed 2025-05-08 | -$12.41M derived: sum of 2 quarters · filed 2025-05-08 | -$21.00M derived: sum of 3 quarters · filed 2025-05-08 | -$32.15M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | -$6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$15.25M derived: sum of 2 quarters · filed 2025-03-19 | -$26.41M derived: sum of 3 quarters · filed 2025-03-19 | -$39.91M 10-K · filed 2025-03-19 | |||
| 2023-09-30 | -$8.58M 10-Q · filed 2024-11-01 | -$19.74M derived: sum of 2 quarters · filed 2024-11-01 | -$33.23M 10-Q · filed 2024-11-01 | -$46.76M derived: sum of 4 quarters · filed 2024-11-01 | |||
| 2023-06-30 | -$11.16M 10-Q · filed 2024-08-12 | -$24.65M 10-Q · filed 2024-08-12 | -$38.18M derived: sum of 3 quarters · filed 2024-08-12 | -$51.80M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | -$13.49M 10-Q · filed 2024-04-29 | -$27.02M derived: sum of 2 quarters · filed 2024-04-29 | -$40.64M derived: sum of 3 quarters · filed 2024-04-29 | -$57.76M derived: sum of 4 quarters · filed 2024-04-29 | |||
| 2022-12-31 | -$13.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$27.15M derived: sum of 2 quarters · filed 2024-03-08 | -$44.27M derived: sum of 3 quarters · filed 2024-03-08 | -$61.21M 10-K · filed 2024-03-08 | |||
| 2022-09-30 | -$13.62M 10-Q · filed 2023-11-06 | -$30.74M derived: sum of 2 quarters · filed 2023-11-06 | -$47.68M 10-Q · filed 2023-11-06 | -$61.15M derived: sum of 4 quarters · filed 2023-11-06 | |||
| 2022-06-30 | -$17.12M 10-Q · filed 2023-07-31 | -$34.06M 10-Q · filed 2023-07-31 | -$47.53M derived: sum of 3 quarters · filed 2023-07-31 | -$60.47M derived: sum of 4 quarters · filed 2023-07-31 | |||
| 2022-03-31 | -$16.94M 10-Q · filed 2023-04-28 | -$30.41M derived: sum of 2 quarters · filed 2023-04-28 | -$43.35M derived: sum of 3 quarters · filed 2023-04-28 | -$55.61M derived: sum of 4 quarters · filed 2023-04-28 | |||
| 2021-12-31 | -$13.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$26.41M derived: sum of 2 quarters · filed 2023-03-09 | -$38.67M derived: sum of 3 quarters · filed 2023-03-09 | -$52.23M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | -$12.94M 10-Q · filed 2022-11-08 | -$25.21M derived: sum of 2 quarters · filed 2022-11-08 | -$38.76M 10-Q · filed 2022-11-08 | -$50.06M derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | -$12.27M 10-Q · filed 2022-07-29 | -$25.82M 10-Q · filed 2022-07-29 | -$37.12M derived: sum of 3 quarters · filed 2022-07-29 | -$47.29M derived: sum of 4 quarters · filed 2022-07-29 | |||
| 2021-03-31 | -$13.55M 10-Q · filed 2022-04-29 | -$24.85M derived: sum of 2 quarters · filed 2022-04-29 | -$35.02M derived: sum of 3 quarters · filed 2022-04-29 | -$41.36M derived: sum of 4 quarters · filed 2022-04-29 | |||
| 2020-12-31 | -$11.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | -$21.47M derived: sum of 2 quarters · filed 2022-02-17 | -$27.81M derived: sum of 3 quarters · filed 2022-02-17 | -$33.64M 10-K · filed 2022-02-17 | $33.64M 10-K · filed 2021-03-29 | ||
| 2020-09-30 | -$10.17M 10-Q · filed 2021-11-04 | $10.17M 10-Q · filed 2020-12-11 | -$16.50M derived: sum of 2 quarters · filed 2021-11-04 | -$22.34M 10-Q · filed 2021-11-04 | $22.34M 10-Q · filed 2020-12-11 | $2.52M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$6.34M 10-Q · filed 2021-08-05 | -$12.17M 10-Q · filed 2021-08-05 | $12.69M derived: sum of 3 quarters · filed 2021-08-05 | $17.51M derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-03-31 | -$5.83M 10-Q · filed 2021-05-04 | $19.02M derived: sum of 2 quarters · filed 2021-05-04 | $23.85M derived: sum of 3 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | $24.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $29.68M derived: sum of 2 quarters · filed 2021-03-29 | $38.97M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | $4.83M 10-Q · filed 2020-12-11 | $14.12M 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |